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Appendix 4, Figure 1. NCSC’s growth in culture (a) and immunostainings with appropriate biomarkers. 
(b) Nerve Growth Factor (p75) Receptor – neural crest marker; (c) Sox10 transcription factor, crucial 
for neural crest induction, migration and differentiation; (d) Mash1, transcription factor that serves as 
an early neuronal marker; (e) staining with Ret H-300 antibody in 2nd day of culture; (f) staining with 
Ret H-300 antibody in 5th day of culture; (g) nestin, neuronal marker; (h) Ret/nestin double 
immunostaining; (i); Glial Fibrillary Acidic Protein (GFAP), glia cells marker; (j) Ret/GFAP double 
immunostaining; (k) staining with Ret (P)Y1062 antibody, cells stimulated with Gdnf; (l) staining with 
Ret (P)Y1062 antibody, cells unstimulated;
